METTL17 and cancer: Concurrently, intracellular and mitochondrial ROS levels were significantly elevated in METTL17 knockdown cancer cells following ML162 treatment, as demonstrated by DCFH-DA and MitoSOX staining (Fig. 4I and Supplementary Fig. 6A and B).